NCT06324877View on ClinicalTrials.gov

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside

NANot yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Ataxia Telangiectasia
Interventions
DRUG

Nicotinamide riboside

Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses

Trial Locations (1)

4101

Queensland Children's Hospital, Brisbane

All Listed Sponsors
lead

The University of Queensland

OTHER

NCT06324877 - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside | Biotech Hunter | Biotech Hunter